Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $20.08, but opened at $19.0001. Chugai Pharmaceutical shares last traded at $19.25, with a volume of 6,659 shares changing hands.
Analyst Ratings Changes
Several equities analysts recently weighed in on CHGCY shares. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Report on CHGCY
Chugai Pharmaceutical Trading Down 4.5%
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. As a group, sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.
Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.
Recommended Stories
- Five stocks we like better than Chugai Pharmaceutical
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
- Meta’s Muse Is Taking Aim at E-Commerce, But Amazon Isn’t Playing Along
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
